文献速递妇科产科

Sacituzumab govitecan靶向Trop-2在子宫浆液性癌的体内外活性

In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
PubMed 文献 · Gynecol Oncol · 2019-12-12

本研究评估了Trop-2在子宫浆液性癌(USC)中的表达及抗体药物偶联物sacituzumab govitecan(SG)的临床前活性。免疫组化显示95.1%(99/104)的USC样本表达Trop-2;过表达Trop-2的原代细胞系对SG的敏感性显著高于对照ADC(p<0.05);SG在Trop-2+异种移植瘤中抑制生长并延长生存(p<0.05)。

要点

  • 免疫组化检测显示95.1%(99/104)的USC样本表达Trop-2。
  • 过表达Trop-2的原代USC细胞系对SG的敏感性显著高于对照ADC(p<0.05)。
  • SG在Trop-2+ USC异种移植瘤中抑制生长并延长生存(p<0.05)。

核心结论

  • SG在体外和体内对过表达Trop-2的USC均表现出显著活性,结果支持在晚期/复发性USC患者中开展SG的临床开发。

研究设计与样本

  • 临床前研究:采用免疫组化和流式细胞术评估USC组织及原代肿瘤细胞系的Trop-2表达和细胞活力;体外通过4小时铬释放试验评估ADCC;体内通过静脉给予SG、对照ADC和hRS7测试对Trop-2+ USC异种移植瘤的活性。

主要发现

  • 免疫组化检测显示95.1%(99/104)的USC样本表达Trop-2。
  • 过表达Trop-2的原代肿瘤细胞系对SG的敏感性显著高于对照ADC(p<0.05)。
  • SG和hRS7均可在Trop-2+ USC细胞系中介导ADCC,而对Trop-2-细胞未检测到细胞毒性。
  • SG与Trop-2+肿瘤混合时对Trop-2-肿瘤诱导显著的旁观者杀伤效应。
  • 在携带Trop-2+异种移植瘤的小鼠中,SG治疗较对照组引起生长抑制并提高生存(p<0.05)。

关键数值与推荐

  • Trop-2免疫组化阳性率:95.1%(99/104 USC样本)。
  • 过表达Trop-2的原代细胞系对SG vs 对照ADC的敏感性差异:p<0.05。
  • SG治疗组 vs 对照组在Trop-2+异种移植瘤小鼠中的生长抑制和生存获益:p<0.05。

临床怎么用

  • 原文结论支持在晚期/复发性USC患者中进一步临床开发SG。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Uterine serous carcinoma (USC) is an aggressive variant of endometrial cancer with poor prognosis. Sacituzumab govitecan (SG) is a novel antibody-drug-conjugate (ADC) targeting trophoblast cell-surface antigen 2 (Trop-2), a transmembrane-calcium-signal-transducer, to deliver SN-38, the active metabolite of irinotecan. The objective of this study was to evaluate the expression of Trop-2 in USC and the preclinical activity of SG against primary USC cell-lines and xenografts. METHODS: We used immunohistochemistry (IHC) and flow-cytometry-based assays to evaluate Trop-2 expression and cell-viability in USC tissue and primary tumor-cell-lines after exposure to SG, non-targeting control ADC, and naked antibody hRS7-IgG. Antibody-dependent-cell-cytotoxicity (ADCC) against Trop-2+ and Trop-2- USC cell-lines was evaluated in vitro using 4-hr-Chromium-release-assays. In vivo activity of SG was tested against Trop-2+ USC xenografts by intravenous administration of SG, control ADC, and hRS7. RESULTS: Trop-2 expression by IHC was detected in 95.1% of USC samples (99/104). Primary tumor cell-lines overexpressing Trop-2 were significantly more sensitive to SG when compared to control ADC (p <0.05). Both SG and hRS7 mediated ADCC in Trop2+ USC cell-lines while no cytotoxicity was detected against Trop-2- cells. SG induced significant bystander killing of Trop-2- tumors when admixed with Trop-2+ tumors. SG caused growth-inhibition and increased survival in SG treated mice harboring Trop-2+ xenografts when compared to controls (p <0.05). CONCLUSIONS: SG is remarkably active against USC overexpressing Trop-2 in vitro and in vivo. Our results combined with SG clinical responses recently reported against multiple chemotherapy resistant human tumors further support clinical development of SG in USC patients with advanced/recurrent disease.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Han C, Perrone E, Zeybek B, et al. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma. Gynecol Oncol. 2019. PMID: 31839338. doi:10.1016/j.ygyno.2019.11.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。